Topical Calcineurin Inhibitors for Dermatological Conditions

Mechanism and Properties

• The American Academy of Dermatology notes that pimecrolimus and tacrolimus are different topical calcineurin inhibitors with similar mechanisms of action but distinct pharmacological properties and formulations 1, 2
• The chemical structure of pimecrolimus and tacrolimus differs, though both belong to the calcineurin inhibitor class 1

Formulation and Efficacy

• The formulation of tacrolimus is an ointment, while pimecrolimus is a cream, according to the American Academy of Dermatology 1, 2
• Tacrolimus has demonstrated higher efficacy in some studies, with 65% of patients clear or almost clear after 8 weeks, compared to 71% for pimecrolimus 1, 2

Safety and Warnings

• The FDA has approved both pimecrolimus and tacrolimus for atopic dermatitis in patients 2 years and older, with a "black box" warning regarding potential malignancy risk, as noted by the American Academy of Dermatology 1, 2
• Both agents can cause burning and itching that generally reduces with continued use, according to the American Academy of Dermatology 1

Clinical Applications

• The American Academy of Dermatology recommends both pimecrolimus and tacrolimus for atopic dermatitis, and off-label use for facial and intertriginous psoriasis 1, 2
• For plaque psoriasis, the combination of tacrolimus with 6% salicylic acid may be used for 12 weeks, as suggested by the American Academy of Dermatology 3

Application and Precautions

• The American Academy of Dermatology advises applying both agents twice daily to affected areas, avoiding application immediately after bathing to reduce irritation 1
• Caution is advised when using either agent in patients receiving ultraviolet light therapy, as noted by the American Academy of Dermatology 1